Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States

References

• National Institutes of Health. National Cancer Institute; Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Myeloma; 2020. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed October 07, 2020.
   Google Scholar
• Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. doi:10.3389/fimmu.2018.01821
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. doi:10.1038/leu.2013.313
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. doi:10.1038/s41408-020-00359-2
   PubMed Web of Science ®Google Scholar
• Verelst SGR, Blommestein HM, De Groot S, et al. Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). Hemasphere. 2018;2(4):e45. doi:10.1097/HS9.0000000000000045
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN guidelines. Multiple myeloma. v2.2021. 2020.
   Google Scholar
• GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf) prescribing information. 2020.
   Google Scholar
• Karyopharm Therapeutics, Inc. XPOVIO (selinexor) prescribing information. 2019.
   Google Scholar
• Montes De Oca R, Bhattacharya S, Vitali N. The anti-BCMA antibody-drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an OX40 agonist potentiates in vivo activity. HemaSphere. 2019;3(S1):231. doi:10.1097/01.HS9.0000560524.63281.bc
   Google Scholar
• Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225–3236. doi:10.1182/blood-2016-01-691162
   PubMed Web of Science ®Google Scholar
• Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–3138. doi:10.1182/blood-2013-10-535088
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37. doi:10.1038/s41408-019-0196-6
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase 2 study. Lancet Oncol. 2020;21(2):207–221. doi:10.1016/S1470-2045(19)30788-0
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653. doi:10.1016/S1470-2045(18)30576-X
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. Epub 2021 Jul 27. doi: 10.1002/cncr.33809
   Google Scholar
• Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204–215.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–1921. doi:10.1038/leu.2016.380
   PubMed Web of Science ®Google Scholar
• Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020;12:317–325. doi:10.2147/CEOR.S251070
   PubMed Web of Science ®Google Scholar
• Runyan A, Banks J, Bruni DS. Current and future oncology management in the United States. J Manag Care Spec Pharm. 2019;25(2):272–281.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291
   PubMed Web of Science ®Google Scholar
• AMCP Format Executive Committee. The AMCP format for formulary submissions: welcome to version 4.0. J Manag Care Spec Pharm. 2016;22(5):444–446.
   Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi:10.1056/NEJMoa1903455
   PubMed Web of Science ®Google Scholar
• Rakesh P, Suvannasankha A, Kapetanakis V, et al. DREAMM-2: assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed/refractory multiple myeloma. Poster presented at the 25th European Hematology Association (EHA) Congress; 2020; Virtual Format.
   Google Scholar
• MacEwan JP, Batt K, Yin W, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leuk Lymphoma. 2018;59(4):941–949. doi:10.1080/10428194.2017.1361035
   PubMed Web of Science ®Google Scholar
• GSK Data on File. GSK study 205678; NCT03525678.
   Google Scholar
• Nikolaou A, Maiese E, Samyshkin Y, et al. Estimating the number of US patients with multiple myeloma at 5 or more Lines of Treatment (LOT). International Society for Pharmacoeconomics and Outcomes Research; 16–19 November, 2020; Virtual. Available from: https://europe2020-ispor.ipostersessions.com/Default.aspx?s=79-B4-D0-A2-C1-BB-30-AE-22-AA-D9-4D-BD-EF-49-8A&pdfprint=true&guestview=true. Accessed August 31, 2021.
   Google Scholar
• US Census Bureau. Annual estimates of the resident population for selected age groups by sex for the United States, Counties, and Puerto Rico Commonwealth and Municipios: April 1, 2010 to July 1, 2018. 2018 population estimates; 2019. Available from: https://www2.census.gov/programs-surveys/popest/tables/2010-2018/counties/asrh/PEPAGESEX.pdf. Accessed November 01, 2019.
   Google Scholar
• Institute for Clinical and Economic Review (ICER). Treatment options for relapsed or refractory multiple myeloma: effectiveness, value, and value-based price benchmarks. Final evidence report and meeting summary; 2016. Available from: https://icer-review.org/announcements/mm-final-report/. Accessed October 07, 2020.
   Google Scholar
• Pelligra CG, Parikh K, Guo S, et al. Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States. Clin Ther. 2017;39(10):1986–2005.e1985. doi:10.1016/j.clinthera.2017.08.010
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, DerSarkissian M, Duh MS, et al. Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma. Clin Ther. 2019;41(3):477–493.e477. doi:10.1016/j.clinthera.2019.01.009
   Web of Science ®Google Scholar
• IBM Micromedex.  RED BOOK® 2019; 2019. Available from: https://www.ibm.com/products/micromedex-red-book. Accessed October 07, 2020.
   Google Scholar
• InHealth. Physicians’ fee & coding guide 2019. Commercial fee range - fees on disc 2019. 2019.
   Google Scholar
• Durie B, Binder G, Pashos C, Khan Z, Hussein M, Borrello I. Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ. 2013;16(5):614–622. doi:10.3111/13696998.2012.760159
   PubMedGoogle Scholar
• Foley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol. 2010;21(7):1455–1461. doi:10.1093/annonc/mdp535
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Campioni M, Benedict Á, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016;19(11):1061–1074. doi:10.1080/13696998.2016.1194278
   PubMed Web of Science ®Google Scholar
• HCUPnet. Weighted national estimates from HCUP National Inpatient Sample (NIS), 2016, Agency for Healthcare Research and Quality (AHRQ), based on data collected by individual States and provided to AHRQ by the States. Statistics by Principal Diagnosis and Payer (insurance status); 2016. Available from: https://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed October 07, 2020.
   Google Scholar